Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII
Open Access
- 1 March 2017
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 15 (3), 411-419
- https://doi.org/10.1111/jth.13597
Abstract
No abstract availableKeywords
Funding Information
- Bayer Pharma AG, Leverkusen, Germany
This publication has 26 references indexed in Scilit:
- Individualizing prophylaxis in hemophilia: a reviewExpert Review of Hematology, 2015
- Guidelines for the management of hemophiliaHaemophilia, 2012
- A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A managementJournal of Thrombosis and Haemostasis, 2012
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)Journal of Thrombosis and Haemostasis, 2011
- Blood‐induced joint disease: the pathophysiology of hemophilic arthropathyJournal of Thrombosis and Haemostasis, 2010
- Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia AJournal of Thrombosis and Haemostasis, 2009
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis StudyJournal of Thrombosis and Haemostasis, 2006
- Practice patterns in haemophilia A therapy – global progress towards optimal careHaemophilia, 2006
- When should prophylactic treatment in patients with haemophilia A and B start?— The German experienceHaemophilia, 1998